Alnylam Pharmaceuticals (ALNY) Revenue (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Revenue came in at $1.3 billion in Q2 2026, up 66.86% YoY from $773.7 million in Q2 2025, and up 10.6% on a QoQ basis from $1.2 billion in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Revenue (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Revenue data on file, last reported at $1.3 billion in Q2 2026.
- Quarterly Revenue rose 66.86% year-over-year to $1.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.8 billion (up 153.15% YoY) and the FY2025 annual result came in at $3.7 billion, up 65.19% from the prior year.
- Revenue grew to $1.3 billion in Q2 2026, from $1.2 billion in the prior quarter.
- In the past five years, Revenue ranged from a high of $1.3 billion in Q2 2026 to a low of $30.0 million in Q1 2025.
- A 5-year average of $595.7 million and a median of $497.6 million in 2024 frame the typical range for Revenue.
- Annual changes were most pronounced in 2025 — Revenue plunged 93.93% — and 2026, when it surged 3790.58%.
- Tracing ALNY's Revenue over 5 years: stood at $335.0 million in 2022, then soared by 31.25% to $439.7 million in 2023, then jumped by 34.9% to $593.2 million in 2024, then surged by 84.95% to $1.1 billion in 2025, then grew by 17.68% to $1.3 billion in 2026.
- The last three Revenue figures came in at $1.3 billion (Q2 2026), $1.2 billion (Q1 2026), and $1.1 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 1.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.29 Bn |
| Mar 31, 2026 | 1.17 Bn |
| Dec 31, 2025 | 1.10 Bn |
| Sep 30, 2025 | 1.25 Bn |
| Jun 30, 2025 | 773.69 Mn |
| Mar 31, 2025 | 594.19 Mn |
| Dec 31, 2024 | 593.17 Mn |
| Sep 30, 2024 | 500.92 Mn |
| Jun 30, 2024 | 659.83 Mn |
| Mar 31, 2024 | 494.33 Mn |
| Dec 31, 2023 | 439.72 Mn |
| Sep 30, 2023 | 750.53 Mn |
| Jun 30, 2023 | 318.75 Mn |
| Mar 31, 2023 | 319.29 Mn |
| Dec 31, 2022 | 335.04 Mn |
| Sep 30, 2022 | 264.31 Mn |
| Jun 30, 2022 | 224.82 Mn |
| Mar 31, 2022 | 213.26 Mn |
| Dec 31, 2021 | 258.54 Mn |
| Sep 30, 2021 | 187.63 Mn |